ClinicalTrials.gg
CompletedNCT07540494Updated Oct 7, 2026

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

A Phase 1 interventional study of 5 Methoxy N,N Dimethyltryptamine and GH001 Aerosol Delivery System in Healthy Adult, sponsored by GH Research Ireland Limited. Completed at 1 site in United States. Open to participants aged 21 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by GH Research Ireland Limited · Phase 1, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
21 Years to 64 Years
Sex
All
01

Study summary

The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration.

02

Conditions studied

  • Healthy Adult

Keywords

  • Mebufotenin
  • 5-MeO-DMT
  • 5-methoxy-N,N-dimethyltryptamine
  • GH001
  • Healthy volunteers
  • Pharmacokinetics
03

In context

Lead sponsor

GH Research Ireland Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) in the range of 18.5 to 35 kg/m2 (inclusive) at screening.
  • Good mental health in the opinion of the investigator.
  • Normal spirometry ( of >80% of predicted and FVC of >80% of predicted value) at screening.

Exclusion criteria

Exclusion Criteria:

  • Has known allergies or or any other to mebufotenin, bufotenin, melatonin or triptans.
  • Has received any medication, including investigational vaccines, in the 90 days prior to baseline or is in the follow-up period of another clinical trial at the time of screening for this trial.
  • Has a current or past condition, which renders the subject unsuitable for the trial according to the investigator's judgement.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    GH001

    A single inhaled dose of GH001 administered via a proprietary aerosol delivery device in 12 subjects

    Drug: 5 Methoxy N,N Dimethyltryptamine · Device: GH001 Aerosol Delivery System

Interventions

  • GH001 administered via inhalation

    Also known as: Mebufotenin, GH001, 5-MeO-DMT

  • DeviceGH001 Aerosol Delivery System

    GH001 aerosol delivery system

06

What researchers measure

Primary outcomes

  1. Serum PK parameters of mebufotenin - maximum observed concentration (Cmax)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  2. Serum PK parameters of mebufotenin - time of maximum observed concentration (Tmax)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  3. Serum PK parameters of mebufotenin - terminal elimination half-life (t1/2)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  4. Serum PK parameters of mebufotenin - area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUClast)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  5. Serum PK parameters of mebufotenin - area under the serum concentration-time curve extrapolated to infinity (AUCinf)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  6. Serum PK parameters of mebufotenin - Partial area under the curve between t1 and t2 (AUCt1-t2)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  7. Serum PK parameters of mebufotenin - terminal elimination rate constant (λz)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  8. Serum PK parameters of mebufotenin - apparent total body clearance (CL/F)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  9. Serum PK parameters of mebufotenin - Apparent volume of distribution (up to bioavailability) following extravascular administration (Vz/F)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  10. Serum PK parameters of mebufotenin - Cmax/AUCinf

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Day 1

  11. Safety and tolerability: incidence of treatment-emergent adverse events

    Incidence of adverse events reported in the study and coded by MedDRA.

    Time frame: Through trial completion, an average of 3 weeks

07

Study locations

1 site
  • GH Research Clinical Trial Site
    Miami, Florida 33319, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in May 2026, 1 month.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Mar 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 20, 2026
StartActual
Mar 18, 2026was Apr 2026
Primary completionActual
May 8, 2026
CompletionActual
May 22, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 7, 2026
Start date
Apr 2026→Mar 18, 2026 (actual)
Oct 7, 2026
Enrollment
12 (estimated)→13 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Completed
    Start date Apr 2026→Mar 18, 2026 (now actual)
    Enrollment 12 (estimated)→13 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07540494
Lead sponsor
GH Research Ireland Limited
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Mar 18, 2026
Primary completion
May 8, 2026
Completion
May 22, 2026
Last update
Oct 7, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxydimethyltryptamines

Start the discussion